Alpha and beta interferons (IFN-␣Type I interferons (IFNs) form a family of multifunctional cytokines initially described for their direct antiviral effect but now also recognized as major elements of the immune response (19,46). Differential activities of IFN subtypes have been reported (3) and used in the clinic for the treatment of various pathologies, including viral hepatitis (IFN-␣2) and multiple sclerosis (IFN-) (32). All type I IFNs are recognized by a single shared receptor composed of two transmembrane proteins, IFNAR1 and IFNAR2. Because of the much faster k on and much slower k off of IFN-␣2 towards IFNAR2 than those measured for IFNAR1 (18,34,40), a two-step assembling mechanism was proposed for the interaction between IFN and the two receptors (Fig. 1B). After binding of IFN-␣2 to IFNAR2 (k a1 ), IFNAR1 transiently associates in a second step to the complex (k a2 ) (18,25). Owing to the short lifetime of the IFN-␣2-IFNAR1 interaction, the complex dissociates (k d2 ) and reassociates (k a2 ) in a fast manner. Thus, depending on the receptor surface concentrations and ligand binding affinities, only part of the bound ligand is involved in the active ternary complex.After formation of the ternary complex, the interferon signal is transduced through the receptor-associated JAK kinases, with the STAT transcription factors as their main targets (3).